As complex drugs see little competition, the FDA will distribute guidelines to increase approvals of generic medicines for ‘economic stability’ and to bring affordable drugs to patients.
Certara has acquired BaseCase Management GmbH, a data visualization company that helps sponsors communicate health economic evidence and product differentiation information.
Recipham has agreed to pay the founders of Nitin Lifescience Limited INR2.8bn ($44m) for the remaining 26% stake they own in the India-based drug manufacturer.
Sponsors using a single-source outsourcing partner could potentially save up to $45m through reduced time to market, according to a recent Tufts study.
Bioprocessing suppliers have recently expressed optimism in the sector despite a slowdown in growth, and one expert believes this will drive investment in new tech and markets.
Thermo Fisher says Patheon will become the most competitive biologics CDMO in the market through direct access to its bioprocessing technologies and capabalities.
AMRI has received a 5-year federal contract award from the National Institutes of Health (NIH) under which it will provide drug substance development and manufacturing services.
Theorem Clinical Research has announced the formation of a strategic alliance with Decision Driver Analytics (DDA) to integrate health economics and outcomes research, predictive modeling and definitive analysis to maximize return on investment for pharmaceutical...
Aurobindo says it can make the loss making European generics operations it is buying from Actavis profitable by combining them with its production network in India.
Pharmaceutics International (Pii) has expanded its range of formulation and process development services with the addition of bioavailability boosting hot-melt extrusion (HME) capabilities.
West Pharmaceutical Services will close a plant in Pennsylvania, US and sell part of a factory Cornwall in the UK to reorganise production operations ahead of impending contract expiries.
Pfizer has welcomed Government commitments to keep Ireland’s 12.5 per cent corporation tax rate in face of recent EU pressure to increase it as a condition of the €85bn 7-year IMF bailout.
RecipharmCobra Biologics has called for more R&D tax breaks in Europe after French Ministry of Higher Education and Research recognises it as key provider.
DSM Biologics says successful XD tech expansion paves way for smaller bioreactors that lowers cost of production facilities and, ultimately, of bio-drug manufacture.
Hyde Engineering + Consulting has opened an office in Dublin, Ireland, enhancing its ability to provide Europe-based biopharm with compliance, qualification and automation services.
There are signs that 2010 will be a better year for the fine and custom chemistry industry but companies at Informex remained cautious and are planning accordingly.
Lonza cuts 2009 earning guidance and may reduce its workforce under “Project Bond” cost cutting plan after a Q3 characterized by an “accumulation of unexpected events”
Pharma’s reliance on outsourcing and products developed by biotechs could cause the pace of innovation to “decline considerably”, according to experts that are concerned about the lack of funding for small businesses.
Facing “unparalleled” challenges MDS is seeking a buyer for its Pharma Services division, and claims to have begun discussions with two interested parties, to allow it to focus on its Nordion business.
AMRI’s adjusted income from operations plummeted by 97 per cent in Q2 as a result of lower demand for contract services, in particular development and small scale manufacture.
The number of pharma employees in New Jersey, US fell by 1,400 in 2008, with R&D expenditure, capital investment and product trials also declining, according to a report.
Synthetech posted a $1.3m (€0.9m) operating profit in fiscal 2009, compared with a $1.1m (€770,000) loss the previous year, but warned that some biotechs and even major pharmas were cutting back.
Neuland has posted a 35 per cent growth in operating profits in its 2008 financial year, despite the pricing pressures and economic environment that have affected the industry.
Winpak appears to have benefited from the current economic turmoil, with lower raw material costs and favourable currency rates helping it post net earnings of $9.7m (€7.4m), up by 62 per cent on 2008.
Patheon and India’s Kemwell have formed an alliance under which they will refer and market each others' services to development and manufacturing clients
The market for packaging machinery is set to grow 5 per cent a year and be worth $40bn (€30.3bn) by 2012, driven partly by a hike in demand for drug products in “pharmerging” economies, according to a new industry report.
Icon's recent $43.2m acquisition of New York-based Prevalere Life Sciences is the latest part of the firm's expansion in the US CRO market. Outsourcing-Pharma spoke with Icon's VP of bioanalytical development, Brian O'Dwyer, and Prevalere...
Contract services firm Marksans Pharmaceutical says that the RPS 1bn (€15.4m) acquisition of UK generics group Relonchem will expand its distribution network and build its presence in the European market.
According to a new report the advent of genetic technologies for
biomarker discovery and drug development is having a positive
knock-on effect for qRT-PCR products, as this technology has given
new hope to the search for biomarkers...
Singapore's commitment to pharmaceutical research and development
goes from strength to strength after its government granted S$7.5bn
(€3.9bn) to sustain the innovation-driven growth the country has
experienced as Asia's...
